TNF and spondyloarthropathy: The efficacy of anti-TNF therapies, particularly infliximab and adalimumab, is reaffirmed by our findings as these agents are crucial for patients with concurrent IBD and spondyloarthritis, particularly when standard treatments fail [39,40].